



MATERIAL SAFETY DATA SHEET

SECTION 1 - IDENTIFICATION OF PRODUCT AND COMPANY

Pfizer Inc
Pfizer Animal Health
235 East 42nd Street
New York, NY 10017

Emergency telephone 1-866-531-8896
Hours of operation 24 Hours
Telephone 1-800-366-5288

Trade names	Temaril-P® Tablets
Product name	Temaril-P® Tablets
Therapeutic use	Antitussive, Antipruritic, Antitussive, Anti-inflammatory
Description	Round, grey tablet

SECTION 2 - COMPOSITION

<u>Ingredient</u>	<u>CAS Number</u>	<u>Amount</u>
Prednisolone (anhydrous)*	50-24-8	<1.0%
Trimeprazine Tartrate*	4330-99-8	<2.0%
Trade Secret	Trade Secret	>97%

*Hazardous

Note: Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety.

SECTION 3 - HAZARDS IDENTIFICATION

Signal word	CAUTION!
Statements of hazard	MAY CAUSE NERVOUS SYSTEM EFFECTS.
Eye effects	None known; however, direct contact with any foreign material may cause eye irritation.
Skin effects	None known
Inhalation effects	Not an expected route of exposure.
Ingestion effects	See 'Other potential health effects', below.
Other potential health effects	This tablet contains material that can alter behavior, produce drowsiness, muscle tremors or rigidity, stupor, or other nervous system effects.

SECTION 3 - HAZARDS IDENTIFICATION ... continued

NOTE: This document has been prepared in accordance with standards for workplace safety, which require the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

SECTION 4 - FIRST AID MEASURES

Skin	Wash hands and arms thoroughly after handling this material. Obtain medical assistance if skin effects occur.
Eyes	Immediately flush eyes with water for at least 15 minutes. If irritation occurs or persists, get medical attention.
Inhalation	Remove to fresh air. If not breathing, give artificial respiration.
Ingestion	In the event of swallowing this material, seek immediate medical attention.
Note to physician	Medical treatment in cases of overexposure should be treated as an overdosage of phenothiazine. Refer to current prescribing information or to local poison control information centers.

SECTION 5 - FIRE FIGHTING MEASURES

General hazard	This mixture is expected to support combustion, based on components present. Toxic or corrosive vapours are expected if this material is heated.
Fire fighting instructions	Wear approved positive pressure, self-contained breathing apparatus and full protective turn out gear. Move containers from fire area if possible without increased personal risk. Dike area if possible to contain water for later disposal.
Extinguishing media	Water, dry powder or foam extinguishers are recommended. Carbon dioxide extinguishers may be ineffective.
Flash point	No data available
Hazardous combustion products	Toxic or corrosive gases are expected in fires involving this mixture.

SECTION 6 - ACCIDENTAL RELEASE MEASURES

General	Review Sections 3, 8 and 12 before proceeding with clean up.
Small spill	Sweep spilled material into an approved container for disposal. Clean spill area thoroughly. Prevent discharge to drains.

SECTION 6 - ACCIDENTAL RELEASE MEASURES ... continued

Large spill	Contain the source of the spill or leak if it is safe to do so. Scoop or shovel spilled material into a labeled container for disposal. Clean spill area thoroughly. Prevent discharge to drains.
--------------------	---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

SECTION 7 - HANDLING AND STORAGE

General handling	IF TABLETS OR CAPSULES ARE CRUSHED AND/OR BROKEN, AVOID BREATHING DUST AND AVOID CONTACT WITH EYES, SKIN AND CLOTHING.
Storage conditions	Avoid prolonged storage at elevated temperatures (greater than room temperature, approximately 20 degrees C). Keep in tightly closed containers or packages away from moisture.

SECTION 8 - EXPOSURE CONTROLS/PERSONAL PROTECTION

Ventilation	Good general ventilation should be sufficient to control airborne levels.
Respiratory protection	Respirators are not required for normal use of this material.
Eye protection	Not required under normal conditions of use.
Skin protection	None required for the normal use of this material. Wash hands and arms thoroughly after handling this material. Clean up spills immediately.
Hand protection	Not required for the normal use of this material.

SECTION 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical form	Round tablet
Color	Gray
Molecular weight	Mixture
Molecular formula	Mixture
pH	Not applicable
Boiling point	Not applicable
Melting point	No data available
Density	Not applicable
Vapor pressure	Not applicable
Water solubility	Components are soluble in water
Solvent solubility	No data available

SECTION 10 - STABILITY AND REACTIVITY

Reactivity	Stable
Conditions to avoid	Direct sunlight, conditions that might generate heat and dispersion as a dust cloud
Incompatibilities	None known
Hazardous decomposition products	No data available
Hazardous polymerization	Not expected to occur
Explosive properties	Not identified. As with many organic dusts, explosions might result when excessive dust concentrations are present.

SECTION 11 - TOXICOLOGY INFORMATION

Acute toxicity				
<u>Compound</u>	<u>Type</u>	<u>Route</u>	<u>Species</u>	<u>Dosage</u>
Prednisolone	LD ₅₀	Oral	Mouse	1680 mg/kg
	LD ₅₀	IP	Rat	2000 mg/kg
Eye	Not determined for this mixture.			
Skin	Not determined for this mixture.			
Inhalation	Not applicable for solid, finished formulations.			
Ingestion	The calculated LD50 is less than 2000 mg/kg, based on effects of individual components and concentrations present.			
Mutagenicity	Not determined for this material.			
Subchronic effects	Not determined for this mixture.			
Chronic effects/ carcinogenicity	Not determined for this mixture.			
Carcinogen status	None of the components of this formulation is listed as a carcinogen by IARC, NTP or OSHA.			
Reproductive effects	Not determined for this material.			
Teratogenicity	Not determined for this material.			
At increased risk from exposure	Depressant effects of some medications or alcohol.			
Additional information	This material contains a phenothiazine tranquiliser.			

SECTION 12 - ECOLOGICAL INFORMATION

Environmental overview	The environmental characteristics of this mixture have not been fully evaluated. Releases to the environment should be avoided.
-------------------------------	---------------------------------------------------------------------------------------------------------------------------------

SECTION 13 - DISPOSAL INFORMATION

Disposal procedure	Collect for recycling or recovery, if possible. Dispose of material on site in a licensed chemical incinerator, if allowed by the incinerator license or permit. If no on-site incinerator is available, dispose of material in a licensed commercial chemical incinerator.
---------------------------	-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

SECTION 14 - TRANSPORTATION INFORMATION

General shipping instructions	Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.
--------------------------------------	----------------------------------------------------------------------------

SECTION 15 - REGULATORY INFORMATION

EU Classification	Harmful
--------------------------	---------

EU Labelling	Xn
---------------------	----

EU Label Pictogram(s)	
------------------------------	--



Safety phrases	S22 - Do not breathe dust.
-----------------------	----------------------------

Canadian WHMIS	This product has been classified in accordance with the hazard criteria of the CPR and the MSDS contains all of the information required by the CPR.
-----------------------	------------------------------------------------------------------------------------------------------------------------------------------------------

SECTION 16 - OTHER

Disclaimer	Pfizer Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without a warranty of any kind, expressed or implied.
-------------------	---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------